irAE Management in Detail and Post-Progression Options

Dr. Sondak provides a practical framework for managing irAEs with cemiplimab. He emphasizes countering patients' instinct to hide symptoms for fear of having treatment stopped, explaining that early reporting leads to easier management and better outcomes. He uses accessible language, explaining that checkpoint inhibitors work by boosting the immune system, not by directly killing cancer cells, to help patients understand why immune balance matters. He reassures patients that corticosteroids and other irAE treatments do not compromise antitumor efficacy, and that even patients requiring treatment discontinuation due to severe toxicity have often done well.

Dr. Zager addresses treatment sequencing after progression on first-line immunotherapy. Checkpoint inhibitors remain the gold standard first-line option. For patients ineligible for checkpoint inhibition due to immune-mediated comorbidities or contraindications, EGFR antibodies and chemotherapy are available, though with less durable responses. Combination strategies are emerging: checkpoint inhibition with radiation, anti-EGFR antibodies, or dual immunotherapy. He reinforces that multidisciplinary management involving radiation oncology, dermatology, surgical oncology, and medical oncology is essential to optimizing outcomes and selecting the right sequencing strategy for each patient.